EGFR and metastatic colorectal cancer: Novel biological agents, such as cetuximab (C225, Erbitux®), a recombinant human/mouse monoclonal antibody against epidermal growth factor receptors (EGFR), have recently been shown to improve the clinical benefit for patients with metastatic colorectal cancer (Cunningham et al, 2004; Saltz et al, 2004).